Lymphoma, Follicular: all 964 studies
Page 9 of 10. Open to participants first (242), then studies with results posted, then the rest; newest registration first within each.
- Study of Lymphoma in AsiaCompletedNCT01584141
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaCompletedNCT01523860Phase 2
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
- Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaCompletedNCT01493479Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular LymphomaCompletedNCT01446562Phase 2
- DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402CompletedNCT01406782
- Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular LymphomaCompletedNCT01393756Phase 2
- A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaCompletedNCT01392716Phase 2
- A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT01388959Phase 2
- Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line ChemotherapyStatus unknownNCT01329354Phase 2
- BRIEF Bendamustine and Rituximab In Elderly FollicularTerminatedNCT01313611Phase 2
- Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaTerminatedNCT01307605Phase 2
- A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly PatientsCompletedNCT01303887Phase 3
- Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular LymphomaCompletedNCT01275209Phase 1
- Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)CompletedNCT01250223
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular LymphomaCompletedNCT01208896Phase 2
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular LymphomaWithdrawnNCT01180569Phase 1/2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-ZevalinCompletedNCT01164696
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- Biomarkers in Samples From Patients With Follicular Lymphoma Treated With RituximabCompletedNCT01150643
- S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular LymphomaCompletedNCT01131221
- Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular LymphomaCompletedNCT01130194Phase 2
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineStatus unknownNCT01127841Phase 2
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT01078142Phase 1/2
- DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701CompletedNCT01057459
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Autologous Vaccine for Follicular LymphomaCompletedNCT01022255Phase 1
- Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaCompletedNCT01000753
- Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary PancreatitisTerminatedNCT00987428Not applicable
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and PrednisoneCompletedNCT00933127
- A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaCompletedNCT00930514Phase 1
- Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular LymphomaCompletedNCT00915096
- Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell LymphomaStatus unknownNCT00907348Phase 2
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496CompletedNCT00898963
- S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911CompletedNCT00896922
- GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaStatus unknownNCT00896519Phase 2
- GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaStatus unknownNCT00893477Phase 2
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's LymphomaCompletedNCT00825149Phase 1
- First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.CompletedNCT00801281Phase 3
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular LymphomaStatus unknownNCT00774826Phase 3
- Zevalin® First Line in Follicular LymphomaStatus unknownNCT00772655Phase 2
- FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
- Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00742144Phase 1
- Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular LymphomaStatus unknownNCT00722930Phase 2
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaCompletedNCT00720135Phase 1
- High-Dose Therapy Treatment in Patients With Follicular LymphomaCompletedNCT00696735Phase 3
- Use of Driving Tests to Evaluate Patient Performance on Oral OpioidsActive, not recruitingNCT00659035
- Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's LymphomaTerminatedNCT00651443Phase 1
- Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1
- Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaTerminatedNCT00637832Phase 2
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's LymphomaCompletedNCT00574730Not applicable
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
- Idiotypic Vaccination for Follicular Lymphoma PatientsStatus unknownNCT00530140Phase 2
- Rituximab and Involved Field Radiotherapy in Early Stage Follicular LymphomaCompletedNCT00509184Phase 2
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Vaccination for the Treatment of Previously Untreated or Relapsed Follicular LymphomaCompletedNCT00487305Phase 1
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
- Dietary Intervention in Follicular LymphomaStatus unknownNCT00455416Phase 2
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedNCT00440388Phase 2
- Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular LymphomaStatus unknownNCT00435955Phase 3
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00428142Phase 2
- Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)CompletedNCT00427856Phase 2
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
- Safety and Efficacy of Fludarabine and Cyclophosphamide + RituximabCompletedNCT00393107Phase 2
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00384150Phase 3
- A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00363636Phase 3
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic RegimenWithdrawnNCT00319332Phase 3
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- FCM Versus R-FCM Followed by R-Maintenance or Observation OnlyStatus unknownNCT00317096Phase 3
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
- Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesCompletedNCT00275431Phase 2